Physician profile
Michael K Sopt
NPI 1518905827
$8,908.42
in general payments reported to CMS, 2019-2025
38 companies · $1,612 in 2025
The $1,612 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $1,017 · 2021: $1,362 · 2022: $1,287 · 2023: $1,776 · 2024: $1,421 · 2025: $1,612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,808.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,163.92 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,030.37 | 2019-2025 | |
| Abbvie INC. | $838.84 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $719.68 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $652.98 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $485.00 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $436.01 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $424.82 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $413.38 | 2019-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $256.01 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $254.50 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Amarin Pharma, INC. | $226.48 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $215.34 | 2022-2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $212.44 | 2021-2025 | |
| Glaxosmithkline, LLC. | $189.08 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sopt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.